These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29134417)

  • 1. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses.
    Zeng LP; Ge XY; Peng C; Tai W; Jiang S; Du L; Shi ZL
    Sci China Life Sci; 2017 Dec; 60(12):1399-1402. PubMed ID: 29134417
    [No Abstract]   [Full Text] [Related]  

  • 2. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Tai W; Zhang X; He Y; Jiang S; Du L
    Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.
    Ng OW; Keng CT; Leung CS; Peiris JS; Poon LL; Tan YJ
    PLoS One; 2014; 9(7):e102415. PubMed ID: 25019613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
    Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP
    Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad neutralization of SARS-related viruses by human monoclonal antibodies.
    Wec AZ; Wrapp D; Herbert AS; Maurer DP; Haslwanter D; Sakharkar M; Jangra RK; Dieterle ME; Lilov A; Huang D; Tse LV; Johnson NV; Hsieh CL; Wang N; Nett JH; Champney E; Burnina I; Brown M; Lin S; Sinclair M; Johnson C; Pudi S; Bortz R; Wirchnianski AS; Laudermilch E; Florez C; Fels JM; O'Brien CM; Graham BS; Nemazee D; Burton DR; Baric RS; Voss JE; Chandran K; Dye JM; McLellan JS; Walker LM
    Science; 2020 Aug; 369(6504):731-736. PubMed ID: 32540900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-like WIV1-CoV poised for human emergence.
    Menachery VD; Yount BL; Sims AC; Debbink K; Agnihothram SS; Gralinski LE; Graham RL; Scobey T; Plante JA; Royal SR; Swanstrom J; Sheahan TP; Pickles RJ; Corti D; Randell SH; Lanzavecchia A; Marasco WA; Baric RS
    Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3048-53. PubMed ID: 26976607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
    Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human monoclonal antibody blocking SARS-CoV-2 infection.
    Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ
    Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.
    Ejemel M; Li Q; Hou S; Schiller ZA; Tree JA; Wallace A; Amcheslavsky A; Kurt Yilmaz N; Buttigieg KR; Elmore MJ; Godwin K; Coombes N; Toomey JR; Schneider R; Ramchetty AS; Close BJ; Chen DY; Conway HL; Saeed M; Ganesa C; Carroll MW; Cavacini LA; Klempner MS; Schiffer CA; Wang Y
    Nat Commun; 2020 Aug; 11(1):4198. PubMed ID: 32826914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
    Hou YX; Peng C; Han ZG; Zhou P; Chen JG; Shi ZL
    Virol Sin; 2010 Feb; 25(1):36-44. PubMed ID: 20960282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus.
    Berry JD; Jones S; Drebot MA; Andonov A; Sabara M; Yuan XY; Weingartl H; Fernando L; Marszal P; Gren J; Nicolas B; Andonova M; Ranada F; Gubbins MJ; Ball TB; Kitching P; Li Y; Kabani A; Plummer F
    J Virol Methods; 2004 Sep; 120(1):87-96. PubMed ID: 15234813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.